|
AR095196A1
(es)
|
2013-03-15 |
2015-09-30 |
Regeneron Pharma |
Medio de cultivo celular libre de suero
|
|
JO3701B1
(ar)
*
|
2014-05-23 |
2021-01-31 |
Regeneron Pharma |
مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
|
|
TW201628649A
(zh)
|
2014-10-09 |
2016-08-16 |
再生元醫藥公司 |
減少醫藥調配物中微可見顆粒之方法
|
|
TW202440904A
(zh)
|
2015-08-04 |
2024-10-16 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法（二）
|
|
CN106928326B
(zh)
*
|
2015-12-31 |
2019-12-24 |
中国科学院微生物研究所 |
一种基于二聚化的受体结合区亚单位的冠状病毒疫苗
|
|
US11542332B2
(en)
|
2016-03-26 |
2023-01-03 |
Bioatla, Inc. |
Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
|
|
CN107298712B
(zh)
*
|
2016-04-14 |
2020-04-07 |
中国疾病预防控制中心病毒病预防控制所 |
全人源化抗中东呼吸综合征冠状病毒中和抗体
|
|
TW201815821A
(zh)
*
|
2016-07-18 |
2018-05-01 |
美商再生元醫藥公司 |
抗茲卡病毒抗體及使用方法
|
|
KR102369014B1
(ko)
|
2016-08-16 |
2022-03-02 |
리제너론 파아마슈티컬스, 인크. |
혼합물로부터 개별 항체들을 정량하는 방법
|
|
WO2018039499A1
(en)
|
2016-08-24 |
2018-03-01 |
Regeneron Pharmaceuticals, Inc. |
Host cell protein modification
|
|
EA201990986A1
(ru)
|
2016-10-25 |
2019-09-30 |
Ридженерон Фармасьютикалз, Инк. |
Способы и системы анализа хроматографических данных
|
|
WO2018097603A2
(ko)
*
|
2016-11-23 |
2018-05-31 |
에스케이케미칼 주식회사 |
중동호흡기증후군 코로나바이러스 s 단백질 면역원 조성물 및 이의 제작 방법
|
|
NZ755816A
(en)
*
|
2017-01-19 |
2026-03-27 |
Omniab Inc |
Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
|
|
WO2018215389A1
(en)
|
2017-05-22 |
2018-11-29 |
F. Hoffmann-La Roche Ag |
Therapeutic compounds and compositions, and methods of use thereof
|
|
KR102659791B1
(ko)
|
2017-07-06 |
2024-04-23 |
리제너론 파마슈티칼스 인코포레이티드 |
당단백질을 만들기 위한 세포 배양 과정
|
|
KR101895228B1
(ko)
*
|
2017-08-23 |
2018-10-30 |
대한민국 |
중동호흡기증후군 코로나바이러스의 스파이크 단백질에 대한 단일클론항체 및 이의 용도
|
|
WO2019060062A1
(en)
|
2017-09-19 |
2019-03-28 |
Regeneron Pharmaceuticals Inc. |
METHODS OF REDUCING PARTICLE FORMATION AND COMPOSITIONS FORMED THEREFROM
|
|
WO2019067671A1
(en)
*
|
2017-09-27 |
2019-04-04 |
David Weiner |
DNA ANTIBODY CONSTRUCTS FOR USE IN CORONAVIRUS RESPIRATORY SYNDROME OF THE MIDDLE EAST
|
|
WO2019078600A1
(ko)
*
|
2017-10-19 |
2019-04-25 |
(주)에이티젠 |
중동호흡기증후군 코로나바이러스에 대한 항체 및 이를 이용한 항체역가 측정방법
|
|
BR112020010615A2
(pt)
|
2017-12-22 |
2020-10-27 |
Regeneron Pharmaceuticals, Inc. |
produto farmacêutico proteico, método e sistema para caracterizar impurezas de produto farmacêutico proteico e de fármaco de baixo peso molecular, método para produzir um anticorpo, anticorpo, e, usos do método e do sistema
|
|
WO2019151632A1
(ko)
*
|
2018-01-31 |
2019-08-08 |
(주)셀트리온 |
중동호흡기증후군 코로나바이러스에 중화활성을 갖는 결합 분자
|
|
KR20190093107A
(ko)
*
|
2018-01-31 |
2019-08-08 |
(주)셀트리온 |
중동호흡기증후군 코로나바이러스에 중화활성을 갖는 결합 분자
|
|
CN111655722A
(zh)
|
2018-01-31 |
2020-09-11 |
瑞泽恩制药公司 |
用于表征药物产品杂质的系统和方法
|
|
TW202311746A
(zh)
|
2018-02-02 |
2023-03-16 |
美商再生元醫藥公司 |
用於表徵蛋白質二聚合之系統及方法
|
|
MX2020008988A
(es)
|
2018-02-28 |
2020-09-28 |
Regeneron Pharma |
Sistemas y metodos para la identificacion de contaminantes virales.
|
|
CA3089655C
(en)
|
2018-03-19 |
2026-01-20 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
US12253490B2
(en)
|
2018-03-19 |
2025-03-18 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
US12259355B2
(en)
|
2018-03-19 |
2025-03-25 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
TW202016125A
(zh)
|
2018-05-10 |
2020-05-01 |
美商再生元醫藥公司 |
用於定量及調節蛋白質黏度之系統與方法
|
|
US11696948B2
(en)
|
2018-06-12 |
2023-07-11 |
Kbio Holdings Limited |
Vaccines formed by virus and antigen conjugation
|
|
US11690907B2
(en)
|
2018-06-12 |
2023-07-04 |
Kbio Holdings Limited |
Vaccines formed by virus and antigen conjugation
|
|
CN110616198B
(zh)
*
|
2018-06-19 |
2021-02-19 |
清华大学 |
一种基于黑猩猩腺病毒68型和MERS-CoV全长膜蛋白的新型冠状病毒疫苗
|
|
TWI853823B
(zh)
|
2018-07-02 |
2024-09-01 |
美商里珍納龍藥品有限公司 |
自混合物製備多肽之系統及方法
|
|
KR102682192B1
(ko)
*
|
2018-08-17 |
2024-07-04 |
한림대학교 산학협력단 |
메르스 코로나바이러스 s 단백질에 대한 단클론 항체 및 그 용도
|
|
MY204234A
(en)
|
2018-08-27 |
2024-08-16 |
Regeneron Pharma |
Use of raman spectroscopy in downstream purification
|
|
AU2019333047A1
(en)
|
2018-08-30 |
2020-12-03 |
Regeneron Pharmaceuticals, Inc. |
Methods for characterizing protein complexes
|
|
RU2709659C1
(ru)
*
|
2018-09-06 |
2019-12-19 |
федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации |
Иммунобиологическое средство и способ его использования для индукции специфического иммунитета к вирусу ближневосточного респираторного синдрома (варианты)
|
|
KR102007161B1
(ko)
*
|
2018-11-07 |
2019-08-07 |
대한민국 |
메르스 코로나 바이러스 스파이크 s1 단백질에 특이적으로 결합하는 단클론 항체
|
|
ES2942024T3
(es)
|
2019-01-16 |
2023-05-29 |
Regeneron Pharma |
Métodos para caracterizar enlaces disulfuro
|
|
CN113874394B
(zh)
*
|
2019-02-20 |
2024-01-19 |
和铂抗体有限公司 |
抗体
|
|
EA202192422A1
(ru)
|
2019-03-05 |
2021-12-09 |
Ридженерон Фармасьютикалз, Инк. |
Человеческий сывороточный альбумин в составах
|
|
US11364276B2
(en)
|
2019-03-26 |
2022-06-21 |
National Guard Health Affairs |
Antiviral peptides for treatment of the middle east respiratory syndrome
|
|
WO2020206162A1
(en)
*
|
2019-04-03 |
2020-10-08 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for insertion of antibody coding sequences into a safe harbor locus
|
|
KR102213745B1
(ko)
*
|
2019-04-16 |
2021-02-09 |
주식회사 바이오앱 |
돼지 유행성 설사병 바이러스 백신 조성물 및 이의 제조 방법
|
|
EP3969908A1
(en)
|
2019-05-13 |
2022-03-23 |
Regeneron Pharmaceuticals, Inc. |
Improved competitive ligand binding assays
|
|
CA3152245A1
(en)
*
|
2019-09-23 |
2021-04-01 |
Seoul National University R&Db Foundation |
Anti-mers-cov antibody and use thereof
|
|
US12297451B1
(en)
|
2019-10-25 |
2025-05-13 |
Regeneron Pharmaceuticals, Inc. |
Cell culture medium
|
|
WO2021108548A1
(en)
|
2019-11-25 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Sustained release formulations using non-aqueous emulsions
|
|
MX2022008973A
(es)
|
2020-01-21 |
2022-08-11 |
Regeneron Pharma |
Metodos de desglicosilacion para electroforesis de proteinas glicosiladas.
|
|
KR20210095781A
(ko)
|
2020-01-24 |
2021-08-03 |
주식회사 에이프릴바이오 |
항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
|
|
EP4050035A4
(en)
*
|
2020-02-10 |
2022-12-28 |
Institute of Microbiology of Chinese Academy of Science |
Beta-coronavirus antigen, preparation method therefor and use thereof
|
|
MX2022009476A
(es)
|
2020-02-10 |
2022-08-22 |
Regeneron Pharma |
Anticuerpos anti-tmprss2 y fragmentos de union a antigeno.
|
|
SG11202110145SA
(en)
|
2020-02-26 |
2021-10-28 |
Vir Biotechnology Inc |
Antibodies against sars-cov-2 and methods of using the same
|
|
CN113321713B
(zh)
*
|
2020-02-28 |
2022-11-01 |
深圳市亚辉龙生物科技股份有限公司 |
SARS-CoV-2的重组RBD蛋白及其制备方法
|
|
BR112022017986A2
(pt)
*
|
2020-03-09 |
2022-12-13 |
Abcellera Biologics Inc |
Anticorpos anticoronavírus e métodos de uso
|
|
WO2021183780A1
(en)
*
|
2020-03-11 |
2021-09-16 |
Ibio, Inc. |
Lichenase-covid-19 based vaccine
|
|
BR112022018200A2
(pt)
*
|
2020-03-12 |
2022-11-29 |
Sydney David Cullis Hill |
Tratamento para infecção por coronavírus e toxicidade de citocinas associadas
|
|
WO2021207948A1
(en)
*
|
2020-04-14 |
2021-10-21 |
Tsb Therapeutics (Beijing) Co., Ltd. |
Anti-sars-cov-2 antibodies and uses thereof
|
|
US11365239B2
(en)
|
2020-03-20 |
2022-06-21 |
Tsb Therapeutics (Beijing) Co., Ltd. |
Anti-SARS-COV-2 antibodies and uses thereof
|
|
FI4045533T3
(fi)
|
2020-03-26 |
2024-02-02 |
Univ Vanderbilt |
Ihmisen monoklonaalisia vasta-aineita vakavalle akuutille koronavirus 2 -hengityselinoireyhtymälle (sars-cov-2)
|
|
US20230218571A1
(en)
*
|
2020-04-01 |
2023-07-13 |
Thiogenesis Therapeutics, Inc. |
Cysteamine precursor compounds for the treatment of betacoronavirus infections
|
|
WO2021201679A1
(en)
|
2020-04-01 |
2021-10-07 |
Kiadis Pharma Intellectual Property B.V. |
Compositions and methods targeting coronaviruses
|
|
CR20220552A
(es)
|
2020-04-02 |
2023-01-17 |
Regeneron Pharma |
Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
|
|
US20230399384A1
(en)
*
|
2020-04-24 |
2023-12-14 |
The Board Of Regents Of The University Of Texas System |
Antibodies to coronavirus spike protein and methods of use thereof
|
|
US20230210848A1
(en)
*
|
2020-04-30 |
2023-07-06 |
Fujifilm Toyama Chemical Co., Ltd. |
Coronavirus infection therapeutic agent formed through combination of pyrazine derivative and another coronavirus infection therapeutic drug
|
|
GB202007532D0
(en)
*
|
2020-05-20 |
2020-07-01 |
Alchemab Therapeutics Ltd |
Polypeptides
|
|
WO2021238910A1
(en)
*
|
2020-05-25 |
2021-12-02 |
Guo Bingshi |
Anti-coronavirus spike protein antibodies and uses thereof
|
|
JP2023527352A
(ja)
*
|
2020-05-26 |
2023-06-28 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
抗ｓａｒｓ－ｃｏｖ－２－スパイク糖タンパク質抗体及び抗原結合断片
|
|
CN111606981B
(zh)
*
|
2020-05-27 |
2022-02-08 |
中国医学科学院基础医学研究所 |
Sars-cov冠状病毒s1蛋白多肽及其应用
|
|
CA3181026A1
(en)
|
2020-06-03 |
2021-12-09 |
Samit GANGULY |
Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies
|
|
EP4164673A4
(en)
*
|
2020-06-16 |
2024-12-04 |
HiFiBiO (HK) Limited |
METHODS AND COMPOSITIONS RELATED TO NEUTRALISING ANTIBODIES AGAINST HUMAN CORONAVIRUS
|
|
US20230272050A1
(en)
*
|
2020-06-23 |
2023-08-31 |
Navigo Proteins Gmbh |
Binding protein specific for the spike protein of severe acute respiratory syndrome corona virus 2 (sars-cov-2)
|
|
US20250263468A1
(en)
*
|
2020-07-24 |
2025-08-21 |
Celltrion Inc. |
Binding molecule having neutralizing activity against coronavirus superfamily
|
|
WO2022026807A2
(en)
*
|
2020-07-30 |
2022-02-03 |
Albert Einstein College Of Medicine |
Antibodies targeting sars-cov-2 and uses thereof
|
|
EP4188960A4
(en)
*
|
2020-08-03 |
2024-09-11 |
Janssen Biotech, Inc. |
MATERIALS AND METHODS FOR MULTIDIRECTIONAL BIOTRANSPORTATION IN VIROTHERAPEUTIC PRODUCTS
|
|
US20230357365A1
(en)
*
|
2020-08-07 |
2023-11-09 |
Novelgen Co., Ltd. |
Antiviral composition against coronavirus
|
|
AU2021332355A1
(en)
|
2020-08-31 |
2023-03-23 |
Regeneron Pharmaceuticals, Inc. |
Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
|
|
WO2022054068A1
(en)
*
|
2020-09-14 |
2022-03-17 |
Ramot At Tel-Aviv University Ltd. |
Antibodies for the prevention, treatment and detection of coronavirus infection
|
|
EP4214229A4
(en)
*
|
2020-09-15 |
2025-01-01 |
Duke University |
CORONAVIRUS ANTIBODIES AND THEIR USES
|
|
WO2022067020A1
(en)
*
|
2020-09-24 |
2022-03-31 |
The Broad Institute, Inc. |
Cell-free antibody engineering platform and neutralizing antibodies for sars-cov-2
|
|
CN112379087B
(zh)
*
|
2020-10-21 |
2022-02-11 |
中国医学科学院医学生物学研究所 |
一种应用于新型冠状病毒灭活疫苗的裂解液及抗原解离的方法
|
|
WO2022115588A1
(en)
|
2020-11-25 |
2022-06-02 |
Regeneron Pharmaceuticals, Inc. |
Sustained release formulations using non-aqueous membrane emulsification
|
|
JP2024500409A
(ja)
|
2020-12-17 |
2024-01-09 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
タンパク質封入マイクロゲルの作製
|
|
WO2022150809A1
(en)
*
|
2021-01-05 |
2022-07-14 |
Immunome, Inc. |
Antibody cocktail against sars-cov-2 spike protein
|
|
CN114716541B
(zh)
*
|
2021-01-05 |
2023-07-21 |
中国科学院分子细胞科学卓越创新中心 |
抗冠状病毒的全人广谱中和抗体76e1及其应用
|
|
KR20230134117A
(ko)
|
2021-01-20 |
2023-09-20 |
리제너론 파마슈티칼스 인코포레이티드 |
세포 배양물에서 단백질 역가를 개선시키는 방법
|
|
WO2022159839A1
(en)
*
|
2021-01-22 |
2022-07-28 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Monoclonal antibodies against corovaviruses and uses thereof
|
|
WO2022170126A2
(en)
*
|
2021-02-05 |
2022-08-11 |
Adagio Therapeutics, Inc. |
Compounds specific to coronavirus s protein and uses thereof
|
|
WO2022182662A1
(en)
|
2021-02-23 |
2022-09-01 |
10X Genomics, Inc. |
Compositions and methods for mapping antigen-binding molecule affinity to antigen regions of interest
|
|
JP2024508304A
(ja)
*
|
2021-03-02 |
2024-02-26 |
ノヴァロック バイオセラピューティクス， リミテッド |
Ｃｌａｕｄｉｎ－６に対する抗体およびそれの使用
|
|
IL305156A
(en)
|
2021-03-03 |
2023-10-01 |
Regeneron Pharma |
Systems and methods for quantifying and modifying protein viscosity
|
|
WO2022187626A1
(en)
|
2021-03-05 |
2022-09-09 |
Regeneron Pharmaceuticals, Inc. |
Anti-sars-cov-2-variant-spike glycoprotein antibodies and antigen-binding fragments
|
|
US20240158478A1
(en)
*
|
2021-03-15 |
2024-05-16 |
Emory University |
SARS-CoV-2 Antibodies and Fragments, Therapeutic Uses, Diagnostic Uses, and Compositions Related Thereto
|
|
US20240182551A1
(en)
*
|
2021-04-02 |
2024-06-06 |
The Scripps Research Institute |
Cross-reactive monoclonal antibodies against coronaviruses
|
|
WO2022241200A1
(en)
*
|
2021-05-14 |
2022-11-17 |
Vanderbilt University |
Cross-reactive coronavirus antibodies
|
|
EP4348234B1
(en)
|
2021-06-01 |
2026-04-08 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
IL310012A
(en)
|
2021-07-14 |
2024-03-01 |
Regeneron Pharma |
Antibodies against SARS-COV-2 spike glycoprotein and antigen-binding fragments
|
|
WO2023004431A2
(en)
*
|
2021-07-23 |
2023-01-26 |
The Trustees Of Columbia University In The City Of New York |
Characterization of potent and broadly neutralizing monoclonal antibodies against sars-cov-2, its variants, and related coronaviruses and methods of use
|
|
US20230077710A1
(en)
|
2021-09-08 |
2023-03-16 |
Regeneron Pharmaceuticals, Inc. |
HIGH-THROUGHPUT AND MASS-SPECTROMETRY-BASED METHOD FOR QUANTITATING ANTIBODIES AND OTHER Fc-CONTAINING PROTEINS
|
|
JP2024531800A
(ja)
|
2021-09-20 |
2024-08-29 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
抗体の不均一性を制御する方法
|
|
CN116178530A
(zh)
*
|
2021-09-26 |
2023-05-30 |
上海君实生物医药科技股份有限公司 |
抗体在治疗SARS-CoV-2感染的用途
|
|
WO2023059800A2
(en)
|
2021-10-07 |
2023-04-13 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods of ph modeling and control
|
|
CA3230985A1
(en)
|
2021-10-07 |
2023-04-13 |
Ross BROWNE |
Ph meter calibration and correction
|
|
WO2023244276A2
(en)
*
|
2021-10-13 |
2023-12-21 |
The Wistar Institute Of Anatomy And Biology |
DNA ENCODED ANTIBODIES WITH Fc MODIFICATIONS
|
|
CA3236367A1
(en)
|
2021-10-26 |
2023-05-04 |
Michelle Lafond |
Systems and methods for generating laboratory water and distributing laboratory water at different temperatures
|
|
TW202342510A
(zh)
|
2022-02-18 |
2023-11-01 |
英商Ｒｑ生物科技有限公司 |
抗體
|
|
WO2023178182A1
(en)
|
2022-03-16 |
2023-09-21 |
10X Genomics, Inc. |
Compositions and methods for detection and treatment of coronavirus infection
|
|
WO2024158961A1
(en)
|
2023-01-25 |
2024-08-02 |
Regeneron Pharmaceuticals, Inc. |
Mass spectrometry-based characterization of antibodies co-expressed in vivo
|
|
US20240245779A1
(en)
|
2023-01-25 |
2024-07-25 |
Regeneron Pharmaceuticals, Inc. |
Methods of modeling liquid protein composition stability
|
|
US20240255519A1
(en)
|
2023-02-01 |
2024-08-01 |
Regeneron Pharmaceuticals, Inc. |
Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
|
|
US20240280551A1
(en)
|
2023-02-22 |
2024-08-22 |
Regeneron Pharmaceuticals, Inc. |
System suitability parameters and column aging
|
|
EP4704808A1
(en)
|
2023-05-01 |
2026-03-11 |
Regeneron Pharmaceuticals, Inc. |
Multidose antibody drug products using phenol or benzyl alcohol
|
|
CN121925272A
(zh)
|
2023-09-29 |
2026-04-24 |
瑞泽恩制药公司 |
利用受控成核进行冻干
|
|
WO2025085594A1
(en)
|
2023-10-18 |
2025-04-24 |
Regeneron Pharmaceuticals, Inc. |
Rapid purification of monoclonal antibody from in-process upstream cell culture material
|
|
US20250145662A1
(en)
|
2023-11-02 |
2025-05-08 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing lipase activity using stress
|
|
WO2025166281A1
(en)
|
2024-02-01 |
2025-08-07 |
Regeneron Pharmaceuticals, Inc. |
Platform for charge-detection mass spectrometry analysis of aavs
|
|
WO2025175164A1
(en)
|
2024-02-16 |
2025-08-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
|
|
TW202602489A
(zh)
|
2024-03-15 |
2026-01-16 |
美商再生元醫藥公司 |
作為經穩定的蛋白質調配物之賦形劑的聚山梨醇酯及聚氧乙烯山梨糖醇酐
|
|
WO2026025028A1
(en)
|
2024-07-26 |
2026-01-29 |
Regeneron Pharmaceuticals, Inc. |
Methods of making ultra-high concentrated protein formulations using lyophilization
|
|
WO2026060350A1
(en)
|
2024-09-13 |
2026-03-19 |
Regeneron Pharmaceuticals, Inc. |
Methods of improving photo stability and controlling formation of hmw species in biologic formulations, and biologic formulations produced by the methods
|
|
CN119264262B
(zh)
*
|
2024-09-19 |
2025-09-02 |
中山大学 |
一种双特异性抗体及其应用
|
|
WO2026076201A2
(en)
|
2024-10-03 |
2026-04-09 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for producing therapeutic proteins using single pass tangential flow filtration for in-line concentration and volume reduction of production pools
|
|
WO2026080597A1
(en)
|
2024-10-08 |
2026-04-16 |
Regeneron Pharmaceuticals, Inc. |
Sustained delivery of biologics and non-aqueous manufacture of same
|